Edgewise Therapeutics, Inc. (EWTX) Price Target Raised to $59 on Positive HCM Trial Data

We recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Wall Street Analysts. Edgewise Therapeutics, Inc. is among the best healthcare stocks.

TheFly reported on June 17 that RBC Capital increased its price target for EWTX to $59 from $48 while maintaining an Outperform rating on the shares. The firm highlighted the company’s 12-week results from the ‘7500 HCM trial, noting that the data demonstrated encouraging safety and efficacy outcomes. RBC Capital believes the findings could support a future Phase 3 trial design without the need for titration echocardiograms, potentially improving the therapy’s usability in real-world settings. The firm also emphasized EWTX’s broader cardiology opportunity, citing the potential of ‘7500 and the company’s pipeline to support significant long-term growth.

Edgewise Therapeutics, Inc. (EWTX) Price Target Raised to $59 on Positive HCM Trial Data

Earlier this month, on June 1, Edgewise Therapeutics, Inc. announced a definitive agreement with Servier for the acquisition of sevasemten and its muscular dystrophy business for $1.55 billion in upfront cash and up to $1.1 billion in additional milestone payments, representing potential total consideration of $2.65 billion. The transaction strengthens EWTX’s financial position and allows the company to focus its strategy on advancing its cardiovascular pipeline. Following the deal, Edgewise will shift into a cardiovascular-focused company, with programs including EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for HFpEF, and EDG-003. The company plans to continue progressing its cardiovascular development programs using the enhanced financial flexibility.

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oral medicines for severe muscle diseases, using a unique approach focused on protecting skeletal and cardiac muscles from damage.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Follow Insider Monkey on Google News.